Deletion of the WD40 domain of LRRK2 in zebrafish causes parkinsonism-like loss of neurons and locomotive defect

PLoS Genetics

Volumn 6, Issue 4, 2010, Pages

  Sheng, Donglai ^a   Qu, Dianbo ^a   Kwok, Ken Hon Hung ^a   Ng, Seok Shin ^a   Lim, Adrian Yin Ming ^a   Aw, Sharon Siqi ^a   Lee, Charlie Wah Heng ^a   Sung, Wing Kin ^a   Tan, Eng King ^b   Lufkin, Thomas ^a   Jesuthasan, Suresh ^c,d   Sinnakaruppan, Mathavan ^a   Liu, Jianjun ^a  

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c AGENCY FOR SCIENCE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MORPHOLINE; LRRK2 PROTEIN, HUMAN; LRRK2 PROTEIN, ZEBRAFISH; PROTEIN SERINE THREONINE KINASE; ZEBRAFISH PROTEIN;

ARTICLE; CELL LOSS; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DOPAMINERGIC NERVE CELL; EMBRYO; EMBRYO DEVELOPMENT; ENZYME STRUCTURE; GENE DELETION; GENE OVEREXPRESSION; MOTOR DYSFUNCTION; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSONISM; ZEBRA FISH; ANIMAL; ANIMAL EMBRYO; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MUTATION; NERVE CELL; PROTEIN TERTIARY STRUCTURE; TRANSGENIC ANIMAL;

DANIO RERIO;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; EMBRYO, NONMAMMALIAN; HUMANS; MUTATION; NERVE DEGENERATION; NEURONS; PARKINSONIAN DISORDERS; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; SEQUENCE DELETION; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 77952409692     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1000914     Document Type: Article

References (52)

1. Thomas B, Beal MF (2007) Parkinson's disease. Hum Mol Genet 16 Spec No. 2: R183-194.
2. Douglas MR, Lewthwaite AJ, Nicholl DJ (2007) Genetics of Parkinson's disease and parkinsonism. Expert Rev Neurother 7: 657-666.
3. Schapira AH (2006) Etiology of Parkinson's disease. Neurology 66: S10-23.
4. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44: 595-600.
5. Ross OA (2007) Lrrking in the background: common pathways of neurodegeneration. J Am Geriatr Soc 55: 804-805.
6. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44: 601-607.
7. Fung HC, Chen CM, Hardy J, Hernandez D, Singleton A, et al. (2006) Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease. Mov Disord 21: 880-881.
8. Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, et al. (2006) LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 354: 424-425.
9. Schapira AH (2006) The importance of LRRK2 mutations in Parkinson disease. Arch Neurol 63: 1225-1228.
10. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, et al. (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7: 133-138.
11. Tan EK (2006) Identification of a common genetic risk variant (LRRK2 Gly2385Arg) in Parkinson's disease. Ann Acad Med Singapore 35: 840-842.
12. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL (2008) The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res 86: 1711-1720.
13. Lesage S, Durr A, Brice A (2007) LRRK2: a link between familial and sporadic Parkinson's disease? Pathol Biol (Paris) 55: 107-110.
14. Marin I (2006) The Parkinson disease gene LRRK2: evolutionary and structural insights. Mol Biol Evol 23: 2423-2433.
15. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA (2006) LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29: 286-293.
16. Gandhi PN, Chen SG, Wilson-Delfosse AL (2009) Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res 87: 1283-1295.
17. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, et al. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52: 587-593.
18. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, et al. (2007) LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405: 307-317.
19. Wang D, Tang B, Zhao G, Pan Q, Xia K, et al. (2008) Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener 3: 3.
20. Lee SB, Kim W, Lee S, Chung J (2007) Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun 358: 534-539.
21. Tan EK (2007) The role of common genetic risk variants in Parkinson disease. Clin Genet 72: 387-393.
22. Scheer N, Groth A, Hans S, Campos-Ortega JA (2001) An instructive function for Notch in promoting gliogenesis in the zebrafish retina. Development 128: 1099-1107.
23. Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, et al. (2007) Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155: 208-219.
24. Taymans JM, Van den Haute C, Baekelandt V (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98: 951-961.
25. Li X, Tan YC, Poulose S, Olanow CW, Huang XY, et al. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103: 238-247.
26. Thierry-Mieg D, Thierry-Mieg J (2006) AceView: a comprehensive cDNAsupported gene and transcripts annotation. Genome Biol 7 Suppl 1: S12 11-14.
27. Wang L, Xie C, Greggio E, Parisiadou L, Shim H, et al. (2008) The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucinerich repeat kinase 2. J Neurosci 28: 3384-3391.
28. Greggio E, Zambrano I, Kaganovich A, Beilina A, Taymans JM, et al. (2008) The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283: 16906-16914.
29. Melrose H (2008) Update on the functional biology of Lrrk2. Future Neurol 3: 669-681.
30. Farrer MJ, Hulihan MM, Kachergus JM, Dachsel JC, Stoessl AJ, et al. (2009) DCTN1 mutations in Perry syndrome. Nat Genet 41: 163-165.
31. Li D, Roberts R (2001) WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci 58: 2085-2097.
32. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, et al. (2007) Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16: 1319-1326.
33. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, et al. (2007) The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 120: 857-863.
34. Nagatsua T, Sawadab M (2009) L-dopa therapy for Parkinson's disease: past, present, and future. Parkinsonism Relat Disord 15 Suppl 1: S3-8.
35. Bretaud S, Lee S, Guo S (2004) Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease. Neurotoxicol Teratol 26: 857-864.
36. Lam CS, Korzh V, Strahle U (2005) Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP. Eur J Neurosci 21: 1758-1762.
37. Chen L, Cagniard B, Mathews T, Jones S, Koh HC, et al. (2005) Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280: 21418-21426.
38. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, et al. (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45: 489-496.
39. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, et al. (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A 102: 5215-5220.
40. Bretaud S, Allen C, Ingham PW, Bandmann O (2007) p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J Neurochem 100: 1626-1635.
41. Zhou H, Falkenburger BH, Schulz JB, Tieu K, Xu Z, et al. (2007) Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int J Biol Sci 3: 242-250.
42. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, et al. (2007) Impaired dopamine release and synaptic plasticity in the striatum of PINK1- deficient mice. Proc Natl Acad Sci U S A 104: 11441-11446.
43. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, et al. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278: 43628-43635.
44. Son OL, Kim HT, Ji MH, Yoo KW, Rhee M, et al. (2003) Cloning and expression analysis of a Parkinson's disease gene, uch-L1, and its promoter in zebrafish. Biochem Biophys Res Commun 312: 601-607.
45. Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease. Nature 404: 394-398.
46. Haywood AF, Staveley BE (2004) Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci 5: 14.
47. Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, et al. (2004) Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131: 2183-2194.
48. Cha GH, Kim S, Park J, Lee E, Kim M, et al. (2005) Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci U S A 102: 10345-10350.
49. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, et al. (2005) Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc Natl Acad Sci U S A 102: 8024-8029.
50. Liu Z, Wang X, Yu Y, Li X, Wang T, et al. (2008) A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105: 2693-2698.
51. Marin I (2008) Ancient origin of the Parkinson disease gene LRRK2. J Mol Evol 67: 41-50.
52. Hendricks M, Jesuthasan S (2007) Electroporation-based methods for in vivo, whole mount and primary culture analysis of zebrafish brain development. Neural Dev 2: 6.